DE69633336D1 - Zusamenzetzung enthaltend einen inhibitor des myelin assoziierten glycoproteins (mag), welcher einer veränderten oder mutierten form von mag enthält - Google Patents

Zusamenzetzung enthaltend einen inhibitor des myelin assoziierten glycoproteins (mag), welcher einer veränderten oder mutierten form von mag enthält

Info

Publication number
DE69633336D1
DE69633336D1 DE69633336T DE69633336T DE69633336D1 DE 69633336 D1 DE69633336 D1 DE 69633336D1 DE 69633336 T DE69633336 T DE 69633336T DE 69633336 T DE69633336 T DE 69633336T DE 69633336 D1 DE69633336 D1 DE 69633336D1
Authority
DE
Germany
Prior art keywords
mag
methods
neural
regeneration
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69633336T
Other languages
English (en)
Other versions
DE69633336T2 (de
Inventor
T Filbin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RES FOUNDATION OF CUNY NEW YOR
Original Assignee
RES FOUNDATION OF CUNY NEW YOR
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RES FOUNDATION OF CUNY NEW YOR filed Critical RES FOUNDATION OF CUNY NEW YOR
Application granted granted Critical
Publication of DE69633336D1 publication Critical patent/DE69633336D1/de
Publication of DE69633336T2 publication Critical patent/DE69633336T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DE69633336T 1995-06-27 1996-06-27 Zusamenzetzung enthaltend einen inhibitor des myelin assoziierten glycoproteins (mag), welcher einer veränderten oder mutierten form von mag enthält Expired - Lifetime DE69633336T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56195P 1995-06-27 1995-06-27
US561P 1995-06-27
PCT/US1996/011058 WO1997001352A1 (en) 1995-06-27 1996-06-27 Compositions and methods using myelin-associated glycoprotein (mag) and inhibitors thereof

Publications (2)

Publication Number Publication Date
DE69633336D1 true DE69633336D1 (de) 2004-10-14
DE69633336T2 DE69633336T2 (de) 2005-09-22

Family

ID=21692042

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69633336T Expired - Lifetime DE69633336T2 (de) 1995-06-27 1996-06-27 Zusamenzetzung enthaltend einen inhibitor des myelin assoziierten glycoproteins (mag), welcher einer veränderten oder mutierten form von mag enthält

Country Status (8)

Country Link
US (3) US5932542A (de)
EP (1) EP0835127B1 (de)
JP (2) JP4841017B2 (de)
AT (1) ATE275415T1 (de)
AU (1) AU731044B2 (de)
CA (1) CA2225691A1 (de)
DE (1) DE69633336T2 (de)
WO (1) WO1997001352A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU731044B2 (en) * 1995-06-27 2001-03-22 Research Foundation Of Cuny, Hunter College Compositions and methods using myelin-associated glycoprotein (MAG) and inhibitors thereof
US6479053B1 (en) * 1997-10-23 2002-11-12 President And Fellows Of Harvard College Laser inactivation of inhibitory molecules in central nervous system myelin
US20030108528A1 (en) * 1998-05-19 2003-06-12 Michal Eisenbach-Schwartz Activated t-cells, nervous system-specific antigens and their uses
WO1999060021A2 (en) * 1998-05-19 1999-11-25 Yeda Research And Development Co. Ltd. Use of activated t cells, nervous system-specific antigens for treating disorders of the nevrous system
US6274568B1 (en) * 1998-08-06 2001-08-14 Ronald L. Schnaar Compounds for altering cell surface sialic acids and methods of use therefor
US7741310B2 (en) * 2000-05-05 2010-06-22 Research Foundation Of The City University Of New York Methods for stimulating nervous system regeneration and repair by regulating arginase I and polyamine synthesis
EP1343528A2 (de) * 2000-11-02 2003-09-17 Research Foundation of City University of New York Methoden zur stimulierung der regeneration und reparatur des nervensystems durch hemmung der phosphodiesterase typ 4
GB0103174D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Plc Novel method of treatment
TWI323265B (en) * 2002-08-06 2010-04-11 Glaxo Group Ltd Antibodies
US7842666B2 (en) * 2002-12-20 2010-11-30 Research Foundation Of City University Of New York Inhibitors of myelin-associated glycoprotein (MAG) activity for regulating neural growth and regeneration
GB0306309D0 (en) 2003-03-19 2003-04-23 Glaxo Group Ltd Method of treatment
CA2609701A1 (en) * 2005-05-25 2006-11-30 The Johns Hopkins University Compositions and methods for enhancing axon regeneration
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
CA2647246C (en) 2006-03-30 2015-06-23 Research Foundation Of City University Of New York Stimulation of neuron regeneration by secretory leukocyte protease inhibitor
US8974782B2 (en) 2011-02-07 2015-03-10 Glaxo Group Limited Treatment of stroke comprising anti-MAG antibodies
EP3446699B1 (de) 2012-04-09 2023-06-07 Case Western Reserve University Zusammensetzungen zur behandlung von nervenverletzung durch hemmung der aktivität der lar-phosphatasefamilie
US11229789B2 (en) 2013-05-30 2022-01-25 Neurostim Oab, Inc. Neuro activator with controller
WO2014194200A1 (en) 2013-05-30 2014-12-04 Creasey Graham H Topical neurological stimulation
US11077301B2 (en) 2015-02-21 2021-08-03 NeurostimOAB, Inc. Topical nerve stimulator and sensor for bladder control
US10280386B2 (en) 2015-04-03 2019-05-07 Ecolab Usa Inc. Enhanced peroxygen stability in multi-dispense TAED-containing peroxygen solid
CN111601636A (zh) 2017-11-07 2020-08-28 Oab神经电疗科技公司 具有自适应电路的非侵入性神经激活器
US10870818B2 (en) 2018-06-15 2020-12-22 Ecolab Usa Inc. Enhanced peroxygen stability using fatty acid in bleach activating agent containing peroxygen solid
WO2020264214A1 (en) 2019-06-26 2020-12-30 Neurostim Technologies Llc Non-invasive nerve activator with adaptive circuit
KR20220115802A (ko) 2019-12-16 2022-08-18 뉴로스팀 테크놀로지스 엘엘씨 부스트 전하 전달 기능이 있는 비침습적 신경 액티베이터

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5250414A (en) * 1988-11-04 1993-10-05 Erziehungsdirektion Of The Canton Zurich Diagnostic methods using neurite growth regulatory factors
GB9403250D0 (en) * 1994-02-21 1994-04-13 Univ Mcgill Therapeutic use of myelin-associated glycoprotein (mag)
AU731044B2 (en) * 1995-06-27 2001-03-22 Research Foundation Of Cuny, Hunter College Compositions and methods using myelin-associated glycoprotein (MAG) and inhibitors thereof

Also Published As

Publication number Publication date
JP4841017B2 (ja) 2011-12-21
ATE275415T1 (de) 2004-09-15
EP0835127A1 (de) 1998-04-15
CA2225691A1 (en) 1997-01-16
JPH11508886A (ja) 1999-08-03
US5932542A (en) 1999-08-03
US6203792B1 (en) 2001-03-20
EP0835127B1 (de) 2004-09-08
JP2009073845A (ja) 2009-04-09
AU6401296A (en) 1997-01-30
US6399577B1 (en) 2002-06-04
DE69633336T2 (de) 2005-09-22
AU731044B2 (en) 2001-03-22
WO1997001352A1 (en) 1997-01-16

Similar Documents

Publication Publication Date Title
DE69633336D1 (de) Zusamenzetzung enthaltend einen inhibitor des myelin assoziierten glycoproteins (mag), welcher einer veränderten oder mutierten form von mag enthält
DE69425267D1 (de) 3-(3,4-dioxyphenyl)-pyrrolidine als inhibitonen der typ iv - phosphodiesterase zur behandlung von entzündungskrankheiten
MX9101869A (es) Ciclosporinas, composicion farmaceutica que las contiene y procedimiento para la produccion de las mismas
ATE425750T1 (de) Verwendung von triglyceriden mit mittellangen ketten zur behandlung und vorbeugung der alzheimerschen erkrankung
ATE323482T1 (de) Verwendung von p38 mapk inhibitoren in der behandlung von augenkrankheiten
DE69429527D1 (de) Inhibitoren von beta-amyloid-protein-herstellung
DE69815090D1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
NO962568L (no) Anvendelse av PLA2 inhibitorer som behandling for Alzheimers sykdom
ATE259215T1 (de) Zusammensetzung zur regulierung des hauterscheinungsbildes
DE69432299D1 (de) Multiple Botulinum Toxine zur Behandlung von neuromuskulären Störungen und Zuständen
ATE361752T1 (de) Methoden zur prophylaxe und behandlung von schäden der wahrnehmungshärchenzellen und der cochlearen neuronen
DE69738776D1 (de) Verwendung von naip oder iap für die behandlung und vorbeugung von neuronalen erkrankungen
WO2002045749A8 (en) Methods for stimulating nervous system regeneration and repair by inhibition phosphodiesterase type 4
ATE474597T1 (de) Inhibition des migrations-inhibitions-faktors in der behandlung von krankheiten bei denen eine cytokin-vermittelte toxizität eine rolle spielt
DE69433309D1 (de) Verbeugende oder therapeutische Mittel für die Alzheimer-Krankheit, eine Siebtest-Methode, und die menschliche Tau-Protein-Kinase
FI951298A0 (fi) 2-amino-4-fenyyli-4-oksovoihappojohdannaiset, joilla on kynureninaasia ja/tai kynureniini-3-hydroksylaasia inhiboiva aktiivisuus
DE69838882D1 (de) Pharmazeutisch wirksame verbindungen und methoden zu ihrer anwendung
ATE236156T1 (de) Pyridocarbazol derivate die einen cgmp-pde inhibilierenden effekt haben
PT948604E (pt) Produtos e metodos relacionados com pyk2
ATE196083T1 (de) Verwendung von ferrioxamin-b zur behandlung septischen schocks
DE60137414D1 (de) Zusammensetzungen zur stimulierung der regeneration und der wiederherstellung des nervensystems durch regulierung der arginase 1- und polyamin-synthese
HK1002697A1 (en) A method for regulating neuron development and maintenance
ATE180983T1 (de) Verfahren zum abbau von chinolonen und naphthyridonen
DK0435177T3 (da) 4-Benzyl-5-phenyl-2,4-dihydro-3H-1,2,4-triazol-3-oner samt deres anvendelse som antikonvulsive midler
ATE194360T1 (de) Verfahren und mittel für die herstellung von bindungsproteinen für inhibitoren von plasmaproteinasen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition